Nima Farzan, MBA
Strategic Business Advisor, Pharma
Nima Farzan was most recently CEO & President of PaxVax, Inc a specialty vaccine manufacturer which was acquired by Emergent Biosolutions. Since joining PaxVax in 2011, Mr. Farzan helped the company carve out a distinct position in the vaccines market while assembling a world-class team with expertise from key industry and US government organizations, leading a company that developed, manufactured and commercialized specialty vaccines for neglected markets. Under his leadership, PaxVax commercialized products including Vaxchora® the only FDA approved vaccine for cholera and Vivotif® the only oral vaccine for typhoid fever, and secured more than $105 million investment from Cerberus Capital Management. Mr. Farzan joined PaxVax from Novartis AG where he spent more than seven years in a number of positions of increasing responsibility including pharmaceutical marketing, sales, and development in both global and US positions. In his previous role prior to leaving Novartis, Mr. Farzan served as the Vice President of Marketing for the vaccines business unit of Novartis, where he was responsible for marketing, market access, pricing, and key account sales and helped launch multiple new vaccines. Prior to Novartis, Mr. Farzan worked at DoubleTwist, a genomics company, and was a consultant at The Boston Consulting Group. Mr. Farzan served on the board of the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private alliance designed to prevent public health emergencies and contain global epidemics. He is also a member of Young Presidents Organization (YPO) and holds a Masters of Business Administration from Harvard Business School and a Bachelor of Arts degree in Human Biology from Stanford University.